Experts outline emerging radiopharmaceutical approaches for metastatic castration-resistant prostate cancer

Dr. Pedro Barata and Dr. Johann De Bono discuss the next steps for radiopharmaceutical therapies aimed at metastatic castration-resistant prostate cancer, highlighting how these agents could reshape treatment.

They review several strategic areas, including the use of combination regimens, the promise of alpha‑emitting isotopes, criteria for selecting patients likely to benefit, and how to sequence these therapies with existing options.

The conversation is part of a broader series that examines radiopharmaceutical strategies, safety considerations, and personalized decision‑making, underscoring the ongoing interest in expanding the therapeutic toolbox for this advanced disease.